Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SYNTARA LIMITED Share Issue/Capital Change 2017

Jan 24, 2017

65830_rns_2017-01-24_13414b9f-c1d1-40ed-a79e-d64afb70e968.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Pharmaxis Ltd

ABN

75 082 811 630

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Fully paid ordinary shares

  • 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued
  • 3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

400,000

Issue of fully paid ordinary shares upon exercise of options granted under the Pharmaxis Ltd Employee Option Plan.

+ See chapter 19 for defined terms.

4 Do the +securitiesrank equallyin all respects from the +issuedate with an existing +classofquoted +securities?If the additional +securitiesdonot rank equally, please state:the date from which they dotheextenttowhichtheyparticipateforthenextdividend, (in the case of atrust,distribution)orinterest paymentthe extent to which they donot rank equally, other thaninrelationtothenextdividend,distributionorinterest payment Yes
5 Issue price or consideration 400,000 shares (PXSAAS): exercise price of$nil per share
6 Purpose of the issue(If issuedas consideration forthe acquisition of assets, clearlyidentify those assets) ExerciseofoptionsunderPharmaxisLtdEmployee Option Plan
6a Is the entity an +eligibleentitythathasobtainedsecurityholder approval under rule 7.1A?If Yes, complete sections 6b – 6hin relation to the +securitiesthesubject of this Appendix 3B, andcomply with section 6i No
6b Thedatethesecurityholderresolution under rule 7.1A waspassed n/a
6c +securitiesNumberofissuedwithoutsecurityholderapproval under rule 7.1 n/a

+ See chapter 19 for defined terms.

  • 6d Number of +securities issued with security holder approval under rule 7.1A
  • 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
  • 6f Number of +securities issued under an exception in rule 7.2
  • 6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.
  • 6h If +securities were issued under rule 7.1A for non‐cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
  • 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
  • 7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

n/a

n/a

n/a

n/a

n/a

n/a

25 January 2017

  • See chapter 19 for defined terms.
Number +Class
8 +classNumberandofall+securitiesquotedonASX+securities(includingtheinsection 2 if applicable) 319,106,844 Fully paid ordinary shares
Number +Class
9 +classNumberandofall 15,000 Optionsexpiring13
+securitiesnot quoted on ASX December2016withan
+securities(includingthein exercisepriceof$2.9310
section 2 if applicable) (ASX Code PXSAF)
102,500 Optionsexpiring17June
2017 with an exercise price
of$3.1755(ASXCode
PXSAH)
17,000 Options expiring 9 August
2017 with an exercise price
of$3.2490(ASXCode
PXSAL)
40,000 Optionsexpiring5
November2017withan
exercisepriceof$4.1500
(ASX Code PXSAT)
3,000 Options expiring 7 February
2018 with an exercise price
of$3.1266(ASXCode
4,000 PXSAN)Options expiring 10 April
2018 with an exercise price
of$1.9735(ASXCode
PXSAP)
1,500 Optionsexpiring22June
2018 with an exercise price
of$1.4590(ASXCode
PXSAR)
100,500 Options expiring 11 August
2018 with an exercise price
of$1.6770(ASXCode
PXSAS)
200,000 Optionsexpiring22June
2018 with an exercise price
of$1.4590(ASXCode
PXSAV)
2,500 Options expiring 22 October
2018 with an exercise price
of$1.4660(ASXCode
PXSAAA)

+ See chapter 19 for defined terms.

Number +Class
5,000 Optionsexpiring10
December 2018 with an
exercise price of $1.0207
(ASX Code PXSAAB)
Options expiring 22 June
86,500 2019withanexercise
price of $2.4098 (ASX
Code PXSAAE)
10,000 Optionsexpiring6
September 2020 with a
zero exercise price (ASX
Code PXSAAF)
202,000 Options expiring 28 June
2022 with a zero exercise
price(ASXCode
PXSAG)
30,000 Optionsexpiring17
October 2022 with a zero
exercise price (ASX Code
PXSAAO)
192,750 Options expiring 6 June
2023 with a zero exercise
price(ASXCode
PXSAAP)
9,313,000 Performance Rights (ASX
Code PXSAAS)

+ See chapter 19 for defined terms.

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) n/a

Part 2 - Pro rata issue

11 Issecurityholderapprovalrequired?
12 Is the issue renounceable or non‐renounceable?
13 +securitiesRatioinwhichthewill be offered
14 +Classof +securitiesto which theoffer relates
15 +Recorddatetodetermineentitlements
16 Willholdingsondifferentregisters(orsubregisters)beaggregatedforcalculatingentitlements?
17 Policy for deciding entitlementsin relation to fractions
18 Names of countries in which theentity has security holders whowillnotbesentnewofferdocumentsNote: Security holders must be told how theirentitlements are to be dealt with.
Cross reference: rule 7.7.
19 Closingdateforreceiptofacceptances or renunciations
20 Names of any underwriters

+ See chapter 19 for defined terms.

21 Amount of any underwriting feeor commission
22 Namesofanybrokerstotheissue
23 Feeorcommissionpayabletothe broker to the issue
24 Amountofanyhandlingfeepayabletobrokerswholodgeacceptances or renunciations onbehalf of security holders
25 Iftheissueiscontingentonsecurityholders'approval,thedate of the meeting
26 Date entitlement and acceptanceform and offer documents will besent to persons entitled
27 If the entity has issued options,andthetermsentitleoptionholderstoparticipateonexercise,thedateonwhichnoticeswillbesenttooptionholders
28 Date rights trading will begin (ifapplicable)
29 Date rights trading will end (ifapplicable)
30 Howdosecurityholdersselltheir entitlements in full througha broker?
31 How do security holders sell partof their entitlements through abrokerandacceptforthebalance?
32 How do security holders disposeof their entitlements (except bysale through a broker)?

+ See chapter 19 for defined terms.

33 +Issue date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of +securities (tick one)

(a) Securities described in Part 1

(b) All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the +securities are +equity securities, the names of the 20 largest holders of theadditional +securities,and the number and percentage of additional +securitiesheld by those holders
36 If the +securities are +equity securities, a distribution schedule of the additional+securitiessetting out the number of holders in the categories1 ‐ 1,0001,001 ‐ 5,0005,001 ‐ 10,00010,001 ‐ 100,000100,001 and over
37 A copy of any trust deed for the additional +securities
Entities that have ticked box 34(b)
38 Number of +securitiesfor which+quotationis sought
39 +Class+securitiesofforwhichquotation is sought
40 Do the +securitiesrank equally inall respects from the +issuedatewith an existing +classof quoted+securities?
+securitiesIftheadditionaldonot rank equally, please state:the date from which they dotheextenttowhichtheyparticipateforthenextdividend,(inthecaseofatrust, distribution) or interestpaymentthe extent to which they donot rank equally, other than inrelation to the next dividend,distributionorinterestpayment

+ See chapter 19 for defined terms.

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

Number +Class
42 +classNumberandofall+securitiesquotedonASX+securities(includingtheinclause 38)

+ See chapter 19 for defined terms.

Quotation agreement

  • 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
  • 2 We warrant the following to ASX.
    • The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
    • There is no reason why those +securities should not be granted +quotation.
    • An offer of the + securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

  • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no‐one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
  • 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
  • 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

(Company secretary)

Sign here: .................................................... Date: 25 January 2017

Print name: David McGarvey

+ See chapter 19 for defined terms.